Cumberland Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Cumberland Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.16M	Sell	8,368 -1,008	-11%	-$447K	0.27%	64
2026 Q1	$4.19M	Sell	9,376 -231	-2%	-$108K	0.32%	55
2025 Q4	$4.36M	Sell	9,607 -137	-1%	-$59.1K	0.27%	77
2025 Q3	$3.82M	Sell	9,744 -36,826	-79%	-$15.4M	0.25%	74
2025 Q2	$20.7M	Sell	46,570 -177	-0.4%	-$81.6K	1.44%	22
2025 Q1	$22.7M	Sell	46,747 -579	-1%	-$270K	1.75%	20
2024 Q4	$19.1M	Buy	47,326 +4,126	+10%	+$1.91M	1.33%	22
2024 Q3	$20.1M	Buy	43,200 +14,541	+51%	+$6.98M	1.39%	23
2024 Q2	$13.4M	Sell	28,659 -728	-2%	-$316K	0.98%	27
2024 Q1	$12.3M	Buy	+29,387	New	+$12.4M	0.89%	30
2021 Q1	–	Sell	-115	Closed	-$27K	–	197
2020 Q4	$27K	Buy	+115	New	+$26.4K	﹤0.01%	165

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Cumberland Partners's VRTX Position: Q2 2026 in Review

Cumberland Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 11% in Q2 2026, selling an estimated $447K and leaving 8,368 shares worth $4.16M. The position accounts for 0.27% of the portfolio, ranked #64.

Cumberland Partners first reported a position in VRTX in Q4 2020 and has held it in 11 quarters since. The position peaked at $22.7M in Q1 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Cumberland Partners held 8,368 shares of Vertex Pharmaceuticals worth $4.16M as of Q2 2026.
Cumberland Partners sold 1,008 Vertex Pharmaceuticals shares in Q2 2026, an estimated $447K.
Vertex Pharmaceuticals made up 0.27% of Cumberland Partners's portfolio in Q2 2026, its #64 holding.
Cumberland Partners first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 11 quarters since.
Cumberland Partners's Vertex Pharmaceuticals position peaked at $22.7M in Q1 2025.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Cumberland Partners's 13F filing for Q2 2026, filed 6 Aug 2026.